News

Novogen and Marshall Edwards (MSHL) have signed a license agreement for MSHL to develop and commercialize the oncology compound, NV-128. The terms of the license consist of –

US-based Merck and Schering-Plough, and their cholesterol JV, Merck/Schering-Plough Pharmaceuticals (MSP) have signed an agreement to resolve the civil class action litigation for $41.5 million. The lawsuit, currently

Law firm, Shalov Stone Bonner & Roccohas has filed a lawsuit seeking a class action status (on behalf of purchasers of the securities of Caraco) in US District

GeoVax has provided updates on its ongoing and planned human clinical trials – Phase 2a Preventive and Phase 1 Therapeutic (in the planning stage). The Preventative trial, designated

Anesiva and Arcion have signed a definitive merger agreement. The merger is likely to result in a public company with a portfolio of late-stage targeted pain therapeutics. The

Baxter has completed production of its first commercial batches of celvapan A/H1N1 pandemic vaccine, and is discussing plans for distribution with national health authorities. Baxter plans to deliver

Novavax has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus, under current good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville.

Labopharm has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada, for its novel formulation of the antidepressant – trazodone. The company’s NDS

EpiCept has filed a New Drug Submission (NDS) with Health Canada for Ceplene (histamine dihydrochloride), for the treatment of acute myeloid leukemia (AML) patients in first complete remission.